Table 2.
Univariate and Multivariate Analyses for Overall Survival After BM
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variables | P | Hazard ratio | 95% CI | P | Hazard ratio | 95% CI |
| Female vs male | .05 | 0.75 | 1.00–1.78 | .05 | 0.72 | 0.51–1.00 |
| Age <66 vs ≧66 years | .05 | 0.74 | 0.55–1.00 | .17 | 0.78 | 0.55–1.12 |
| ECOG PS 2–3 vs 0–1 | <.0001 | 2.89 | 1.85–4.35 | .008 | 2.02 | 1.22–3.21 |
| EGFR mutated vs wildtype | .01 | 0.69 | 0.52–0.93 | .032 | 0.61 | 0.39–0.96 |
| Single BM | .0006 | 0.59 | 0.43–0.80 | .0057 | 0.61 | 0.43–0.87 |
| The use of EGFR-TKI | .94 | 0.99 | 0.72–1.35 | .6 | 1.13 | 0.72–1.79 |
| Local therapies (SRS, operation) | <.0001 | 0.49 | 0.37–0.67 | .0002 | 0.51 | 0.36–0.72 |
| WBRT | .0037 | 1.56 | 1.16–2.10 | .21 | 1.26 | 0.88–1.80 |
| Use of ICIs | .33 | 0.71 | 0.32–1.36 | .42 | 0.75 | 0.33–1.46 |
The hazard ratio was estimated in a Cox proportional hazard model.
BMs, brain metastases; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy; ICIs, immune checkpoint inhibitors.